Trial Profile
An Open-label, Multicenter Extension Study of Onartuzumab in Patients With Solid Tumors on Study Treatment Previously Enrolled in an F.Hoffmann-la Roche- and/or Genentech- Sponsored Study
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 13 Dec 2022
Price :
$35
*
At a glance
- Drugs Onartuzumab (Primary) ; Bevacizumab; Erlotinib
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Chugai Pharmaceutical; Roche
- 31 Jul 2018 Status changed from active, no longer recruiting to completed.
- 14 Mar 2018 Planned End Date changed from 25 Jan 2018 to 18 May 2018.
- 14 Mar 2018 Planned primary completion date changed from 25 Jan 2018 to 18 May 2018.